08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

GI-5005: Preliminary Phase IIb data

Preliminary data from an open-label Phase IIb trial in 27 patients with the T/T genotype of interleukin-28B (IL-28B; IFNL3 ) showed that GI-5005 plus pegylated interferon and ribavirin produced a 63% virologic response rate vs....
08:00 , Nov 8, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV Protein kinase B (PKB; PKBA; AKT; AKT1); phosphoinositide 3-kinase (PI3K) In vitro studies suggest inhibiting the PI3K and AKT pathway could help prevent...
00:39 , Sep 6, 2012 |  BC Extra  |  Financial News

GlobeImmune sets IPO range

GlobeImmune Inc. (Louisville, Colo.) amended its IPO and now plans to sell 5 million shares at $11-$13 per share. A $12 price would raise $60 million and value the company at $206.8 million. Wells Fargo;...
00:35 , Jul 3, 2012 |  BC Extra  |  Financial News

GlobeImmune proposes IPO

GlobeImmune Inc. (Louisville, Colo.) proposed to raise up to $69 million in an IPO underwritten by Wells Fargo; Piper Jaffray; and JMP Securities. GlobeImmune's portfolio includes two products in Phase IIb testing: GI-4000 for pancreatic...
07:00 , Aug 25, 2011 |  BC Innovations  |  Targets & Mechanisms

More than one way to stop HCV

A French team led by Epixis S.A. has developed an HCV vaccine that triggers both a T cell response and broadly neutralizing antibodies in macaques. 1 Because of the ability to elicit both types of...
08:00 , Nov 15, 2010 |  BioCentury  |  Product Development

Selling short in HCV

With HCV compounds telaprevir and boceprevir now in the homestretch, much of the focus at the American Association for the Study of Liver Diseases meeting was on new details from previously reported Phase III trials....
07:00 , Oct 28, 2010 |  BC Innovations  |  Cover Story

DGAT out of the bag

U.S. and French researchers have shown that DGAT1 , an enzyme involved in lipid droplet biogenesis, is a host factor for HCV infection. 1 The results have prompted Via Pharmaceuticals Inc. to consider repurposing its...
07:00 , May 10, 2010 |  BioCentury  |  Product Development

Looking for the right type

Although GlobeImmune Inc. 's GI-5005 Tarmogen immunotherapy failed a Phase IIb trial to treat chronic HCV infection, a new subgroup analysis based on IL-28B genotypes shows improvements in viral clearance were greatest in the genotypes...
00:28 , Jan 20, 2007 |  BC Extra  |  Clinical News

Researchers identify HCV-associated liver disease gene

Researchers from Osaka University and colleagues published in the Proceedings of the National Academy of Sciences that a knockout of the proteasome activator 28 (PA28) gamma gene induces the accumulation of HCV core protein in...